Abvc Biopharma (ABVC) Other Working Capital Changes (2019 - 2026)
Abvc Biopharma's (ABVC) quarterly Other Working Capital Changes came in at -$75109.0 in Q1 2026, up 29.76% YoY from -$57884.5 in Q1 2025, and up 61.97% on a QoQ basis from -$197498.0 in Q4 2025.
Abvc Biopharma (ABVC) Other Working Capital Changes (2019 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 6 years of Other Working Capital Changes data on file, last reported at -$75109.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 29.76% year-over-year to -$75109.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$442661.0 (down 153.58% YoY) and the FY2025 annual result came in at -$474479.0, down 180.93% from the prior year.
- Other Working Capital Changes climbed to -$75109.0 in Q1 2026, from -$197498.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $265785.0 in Q4 2024 to a low of -$204341.0 in Q2 2023.
- A 4-year average of -$3510.4 and a median of $149.0 in 2025 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes soared 13272900.0% — and 2025, when it sank 248.8%.
- Tracing ABVC's Other Working Capital Changes over 4 years: stood at -$1.0 in 2023, then soared by 13272900.0% to $132728.0 in 2024, then slumped by 248.8% to -$197498.0 in 2025, then jumped by 61.97% to -$75109.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$75109.0 (Q1 2026), -$197498.0 (Q4 2025), and -$95919.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79,605.00 |
| Jun 30, 2026 | -79,605.00 |
| Jun 30, 2026 | -79,605.00 |
| Mar 31, 2026 | -75,109.00 |
| Mar 31, 2026 | -75,109.00 |
| Mar 31, 2026 | -75,109.00 |
| Dec 31, 2025 | -197,498.00 |
| Dec 31, 2025 | -197,498.00 |
| Dec 31, 2025 | -197,498.00 |
| Sep 30, 2025 | -95,919.00 |
| Sep 30, 2025 | -95,919.00 |
| Sep 30, 2025 | -95,919.00 |
| Jun 30, 2025 | -74,135.00 |
| Jun 30, 2025 | -74,135.00 |
| Jun 30, 2025 | -74,135.00 |
| Mar 31, 2025 | -106,927.00 |
| Mar 31, 2025 | -106,927.00 |
| Mar 31, 2025 | -106,927.00 |
| Dec 31, 2024 | 132,728.00 |
| Dec 31, 2024 | 132,728.00 |